Intervention | Base case | Base case without 018 study group | Base case without 018 study group; with AI4463023 + TBVIG |
---|---|---|---|
Fixed effects analyses | |||
Entecavir 0.5 mg | 1.00 (Baseline) | 1.00 (Baseline) | 1.00 (Baseline) |
Adefovir 10 mg | 0.33 (0.14, 0.62) | 0.23 (0.05, 0.56) | 0.33 (0.10, 0.70) |
Lamivudine 100 mg | 0.38 (0.22, 0.58) | 0.38 (0.22, 0.58) | 0.52 (0.41, 0.64) |
Placebo | 0.01 (0.00, 0.03) | 0.00 (0.00, 0.02) | 0.01 (0.00, 0.03) |
Telbivudine 600 mg | 0.67 (0.43, 0.92) | 0.67 (0.44, 0.92) | 0.86 (0.71, 1.01) |
Tenofovir 245 mg | 1.27 (0.96, 1.47) | 1.12 (0.61, 1.43) | 1.25 (0.84, 1.48) |
Interferon alpha | 0.14 (0.05, 0.29) | 0.13 (0.05, 0.29) | 0.20 (0.08, 0.37) |
Peginterferon alpha-2a/2b | 0.23 (0.11, 0.39) | 0.22 (0.11, 0.39) | 0.32 (0.21, 0.46) |
Residual deviance | 19.48 | 17.10 | 21.54 |
DIC | 35.56 | 32.14 | 39.15 |
Random effects analyses | |||
Entecavir 0.5 mg | 1.00 (Baseline) | 1.00 (Baseline) | 1.00 (Baseline) |
Adefovir 10 mg | 0.33 (0.07, 0.82) | 0.27 (0.03, 0.95) | 0.29 (0.04, 0.78) |
Lamivudine 100 mg | 0.37 (0.09, 0.84) | 0.42 (0.07, 1.09) | 0.51 (0.23, 0.86) |
Placebo | 0.01 (0.00, 0.06) | 0.01 (0.00, 0.07) | 0.01 (0.00, 0.04) |
Telbivudine 600 mg | 0.64 (0.18, 1.19) | 0.72 (0.12, 1.39) | 0.86 (0.41, 1.27) |
Tenofovir 245 mg | 1.21 (0.48, 1.51) | 1.08 (0.22, 1.52) | 1.15 (0.39, 1.50) |
Interferon alpha | 0.16 (0.01, 0.67) | 0.20 (0.01, 0.94) | 0.22 (0.03, 0.67) |
Peginterferon alpha-2a/2b | 0.25 (0.03, 0.88) | 0.30 (0.02, 1.13) | 0.34 (0.07, 0.88) |
Residual deviance | 18.23 | 16.12 | 19.78 |
DIC | 35.86 | 32.10 | 39.07 |